Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Efficacy and safety of blinatumomab as frontline treatment for infant acute lymphoblastic leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

WLWei LinJFJia FanYWYing Wu

Discussion

Loading...

Member takes

Overview

Retrospective analysis demonstrates improved minimal residual disease rates with blinatumomab in infant acute lymphoblastic leukemia, indicating potential for effective immunotherapy.

Key Points

  • Ten patients achieved minimal residual disease negativity after treatment with blinatumomab, showing its efficacy in early therapy.
  • Adverse events were manageable, with only mild cytokine release syndrome reported among the infant cohort.
  • Infants receiving blinatumomab combined with chemotherapy showed favorable outcomes in pediatric leukemia management.
  • Longer follow-up and larger studies are needed to confirm findings and enhance treatment strategies for infant acute lymphoblastic leukemia.

Cite This Study

Lin et al. (2025) studied this question.

synapsesocial.com/papers/69362f7d4fa91c937236e4e0https://doi.org/10.1182/blood-2025-6860
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Leukemia Burden Impacts the Efficacy and Toxicity of Blinatumomab in Pediatric B‐Cell Acute Lymphoblastic Leukemia2025
  2. 2Blinatumomab in pediatric B-acute lymphoblastic leukemia2025 · 6 citations
  3. 3Blinatumomab combined with low-dose chemotherapy and tyrosine kinase inhibitors as first-line induction for newly diagnosed Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia: improved efficacy and reduced toxicity2025
  4. 4Low-intensity cytoreduction with low-dose cytarabine prior to blinatumomab for pediatric and AYA R/R ALL integrated with multi-omics analysis to discover predictive biomarkers: Initial results from JPLSG-ALL-R19-blin2025
  5. 5Blinatumomab vs. chemotherapy in pediatrics B-cell ALL: A meta-analysis of randomized controlled trials2025